Bridgeway Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$211K Sell
75,996
-1,304
-2% -$5.26K ﹤0.01% 1011
2026
Q2
$375K Hold
77,300
– – 0.01% 923
2026
Q1
$181K Hold
77,300
– – ﹤0.01% 1052
2025
Q4
$104K Hold
77,300
– – ﹤0.01% 1119
2025
Q3
$117K Hold
77,300
– – ﹤0.01% 1091
2025
Q2
$89.7K Sell
77,300
-75,000
-49% -$98.9K ﹤0.01% 1089
2025
Q1
$242K Sell
152,300
-22,700
-13% -$49K 0.01% 879
2024
Q4
$530K Buy
+175,000
New +$574K 0.01% 802

Other funds holding ZNTL

Bridgeway Capital Management's ZNTL Position: Q3 2026 in Review

Bridgeway Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 1.7% in Q3 2026, selling an estimated $5.26K and leaving 75,996 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.

Bridgeway Capital Management first reported a position in ZNTL in Q4 2024 and has held it in 8 quarters since. The position peaked at $530K in Q4 2024. 128 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

  • Bridgeway Capital Management held 75,996 shares of Zentalis Pharmaceuticals worth $211K as of Q3 2026.
  • Bridgeway Capital Management sold 1,304 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $5.26K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1011 holding.
  • Bridgeway Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • Bridgeway Capital Management's Zentalis Pharmaceuticals position peaked at $530K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.